Dr. Praveen Patidar

Praveen Patidar, PhD

Associate Professor

Chemistry

Education

Postdoctoral Research, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX

PhD. (Biochemistry), New Mexico State University, Las Cruces, NM

M.S. (Life Sciences), Devi Ahilya University, Indore, MP (India)

B.S. (Biology/Chemistry), Holkar Science College, Indore, MP (India)

Research Interests

Genome maintenance is an essential cellular task. Compromised genomic integrity results in several debilitating diseases such as neurodegenerative disorders, autoimmune diseases, and cancer. Genomic integrity is constantly challenged due to the intrinsic susceptibility of DNA to various kinds of damage from exposure to various endogenous (e.g., reactive oxygen species, R-loops, replication stress) and exogenous (radiation, chemical mutagens) factors. The intricate task of genome maintenance is promoted by myriads of proteins involved in preventing, recognizing and resolving DNA damage.

The Patidar lab is interested in understanding the mammalian DNA damage and repair response with emphasis on delineating the molecular functions of novel DNA repair proteins and seeking translational research avenues. We are also interested in developing anti-cancer drugs that create DNA damage and trigger cell death exclusively in cancer cells. Interdisciplinary approaches including protein biochemistry, cell & molecular biology, cancer biology, genomics, proteomics and RNAi are routinely employed to drive on-going research.

1R15GM150071-01, National Institutes of Health/NIGMS, “XRN2-DDX23 Cooperation in Avoiding R-loop-induced Genomic Instability”.  Role: Principal Investigator

1R15GM128071-01A1, National Institutes of Health/NIGMS, “The Interplay of XRN2 and PARP1 in Preventing R-loop-induced Genomic Instability”. Role: Principal Investigator

Recent Publications

Viera T, Abfalterer Q, Neal A, Trujillo R, Patidar PL. Molecular Basis of XRN2-Deficient Cancer Cell Sensitivity to Poly(ADP-ribose) Polymerase Inhibition. Cancers (Basel). 2024 Jan 30;16(3). doi: 10.3390/cancers16030595. PubMed PMID: 38339346; PubMed Central PMCID: PMC10854503.

Ellepola N, Viera T, Patidar PL, Rubasinghege G. Fate, transformation and toxicological implications of environmental diclofenac: Role of mineralogy and solar flux. Ecotoxicol Environ Saf. 2022 Nov;246:114138. doi: 10.1016/j.ecoenv.2022.114138. Epub 2022 Oct 3. PubMed PMID: 36201921.

Viera CR, Stevens BT, Viera T, Zielinski C, Uranga LA, Rogelj S, Patidar PL, Tello-Aburto R. Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents. R Soc Open Sci. 2022 Sep;9(9):220358. doi: 10.1098/rsos.220358. eCollection 2022 Sep. PubMed PMID: 36177203; PubMed Central PMCID: PMC9515629.

Viera T, Patidar PL. DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition. Sci Rep. 2020 Nov 19;10(1):20210. doi: 10.1038/s41598-020-76850-4. PubMed PMID: 33214574; PubMed Central PMCID: PMC7677541.

Patidar PL, Viera T, Morales JC, Singh N, Motea EA, Khandelwal M, Fattah FJ. XRN2 interactome reveals its synthetic lethal relationship with PARP1 inhibition. Sci Rep. 2020 Aug 28;10(1):14253. doi: 10.1038/s41598-020-71203-7. PubMed PMID: 32859985; PubMed Central PMCID: PMC7455564.

Ellepola N, Ogas T, Turner DN, Gurung R, Maldonado-Torres S, Tello-Aburto R, Patidar PL, Rogelj S, Piyasena ME, Rubasinghege G. A toxicological study on photo-degradation products of environmental ibuprofen: Ecological and human health implications. Ecotoxicol Environ Saf. 2020 Jan 30;188:109892. doi: 10.1016/j.ecoenv.2019.109892. Epub 2019 Nov 12. PubMed PMID: 31732272; PubMed Central PMCID: PMC6893141.

Please visit link below for the complete publication list,

https://www.ncbi.nlm.nih.gov/myncbi/1lwzQs9q7c697M/bibliography/public/

Patents

“KP372-1-induced DNA damage as a chemotherapeutic approach to treat cancer”, Patidar P.L. and Viera, T., U.S. Patent Application No. 17/523,002.

“Kub5/Hera as a determinant of sensitivity to DNA damage”, Boothman D.A., Motea E. A., Patidar P. L. and Morales J. C., U.S. Patent Application No. 62/132,985.

“XRN2 as a determinant of sensitivity to DNA damage”, Boothman D.A., Motea E. A., Morales J. C. and Patidar P. L., U.S. Provisional Patent Application No. 62/340,782.